Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-3 peptide + Melan-A peptide + gp100 peptide + NA17 peptide + autologous peripheral blood mononuclear cells
- Development stage
- Phase 2
- Lead developer
- CHU de Nantes
- Modality
- Cell Therapies, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
This investigational immunotherapy is an autologous cell-based vaccine designed for the treatment of metastatic melanoma. The therapy consists of peripheral blood mononuclear cells (PBMCs) harvested from the patient, which are subsequently pulsed or loaded with four specific HLA-A2-restricted melanoma-associated peptides: MAGE-3 (Melanoma-associated antigen 3), Melan-A (MART-1), gp100 (Melanocyte protein PMEL), and NA17 (N-acetylglucosaminyltransferase V). The mechanism of action involves using the autologous PBMCs as antigen-presenting cells to prime and activate the patient's own cytotoxic T lymphocytes (CTLs) against tumor cells expressing these specific antigens. This multi-antigen approach is intended to overcome tumor heterogeneity and reduce the risk of immune escape, a common challenge in single-antigen cancer vaccines.
- Other names
- multi-epitope-pulsed PBMC vaccineMAGE-3/Melan-A/gp100/NA17-pulsed PBMCsmulti-peptide-pulsed autologous peripheral blood mononuclear cells
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on MAGE-3 peptide + Melan-A peptide + gp100 peptide + NA17 peptide + autologous peripheral blood mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-3 peptide + Melan-A peptide + gp100 peptide + NA17 peptide + autologous peripheral blood mononuclear cells.